David Young
Known title: President & CEOCIK: 0001378166
David Young's purchase track record
How the stock did after each of David Young's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 11 since April 11, 2023
Stock higher 6 months later
17%
3 months: 18%
Median 6-month return
-37.9%
3 months: -19.1%
Beat the S&P 500
17%
median -51.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2026 | PCSA | $5K | -8.3% | pending | — |
| 6/15/2026 | PCSA | $5K | -14.0% | pending | — |
| 5/29/2026 | PCSA | $5K | -19.1% | pending | — |
| 5/15/2026 | PCSA | $5K | -17.9% | pending | — |
| 4/30/2026 | PCSA | $5K | -24.4% | pending | — |
| 4/15/2026 | PCSA | $5K | -19.3% | -45.4% | +9.9% |
| 3/31/2026 | PCSA | $5K | -24.0% | -30.3% | +17.5% |
| 1/27/2025 | PCSA | $99K | -61.6% | -62.1% | +6.3% |
| 2/6/2024 | PCSA | $102K | +4.2% | -21.9% | +5.8% |
| 6/12/2023 | PCSA | $32K | -60.3% | +14.4% | +6.5% |
| 4/11/2023 | PCSA | $40K | +10.0% | -56.1% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PCSA | ▲ Buy | Open Market | 2,531 | $5K | 6/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,067 | $5K | 6/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,786 | $5K | 5/29/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,545 | $5K | 5/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,706 | $5K | 4/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,545 | $5K | 4/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,810 | $5K | 3/31/2026 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 49 | $0 | 1/1/2026 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 17,272 | — | 4/1/2025 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 5,345 | $2K | 4/1/2025 | View on chart |
| PCSA | ▲ Buy | Open Market | 124,500 | $99K | 1/27/2025 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 644 | — | 7/10/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 282 | $482 | 7/10/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 4/5/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 518 | $1K | 4/5/2024 | View on chart |
| PCSA | ▲ Buy | Open Market | 21,000 | $52K | 2/7/2024 | View on chart |
| PCSA | ▲ Buy | Open Market | 20,000 | $51K | 2/6/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 1/1/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 518 | $1K | 1/1/2024 | View on chart |
| PCSA | ▲ Buy | Grant | 155,277 | $45K | 10/12/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 142,000 | $34K | 10/10/2023 | View on chart |
| PCSA | ▲ Buy | Open Market | 40,000 | $32K | 6/12/2023 | View on chart |
| PCSA | ▲ Buy | Open Market | 20,000 | $11K | 4/14/2023 | View on chart |
| PCSA | ▲ Buy | Open Market | 20,000 | $10K | 4/13/2023 | View on chart |
| PCSA | ▲ Buy | Open Market | 20,000 | $9K | 4/12/2023 | View on chart |
| PCSA | ▲ Buy | Open Market | 20,000 | $10K | 4/11/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 18,750 | $15K | 2/9/2023 | View on chart |
| PCSA | ▼ Sell | Gift | 9,250 | $0 | 8/16/2022 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 7,601 | — | 8/5/2022 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 2,531 | $8K | 8/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.